B. Riley, Foghorn Therapeutics
Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 0.97% of ...
The markets were closed on Monday for Martin Luther King Jr. Day, which also marked the inauguration of Donald J. Trump, the ...
B. Riley analyst Kyle Bauser raised the firm’s price target on ClearPoint Neuro (CLPT) to $20 from $15 and keeps a Buy rating ...
B. Riley issued their Q1 2025 earnings estimates for Customers Bancorp in a research note issued to investors on Monday, ...
In a report released yesterday, Mayank Mamtani from B.Riley Financial maintained a Buy rating on Viking Therapeutics (VKTX – Research Report), ...
Learn about the latest financial trends and strategies in our comprehensive article written by a financial expert.
Analysts at B. Riley reduced their FY2024 earnings estimates for shares of Ladder Capital in a research report issued to clients and investors on Monday, January 27th. B. Riley analyst R. Binner now ...
B. Riley analyst Mike Crawford upgraded Redwire (RDW) to Buy from Neutral with a price target of $27, up from $9.50. The firm increased fiscal ...
Chairman Bryant Riley has put a priority on paying down debt as his firm seeks to recover from a string of losses.
B. Riley boosted their FY2025 EPS estimates for shares of Customers Bancorp in a research report issued to clients and investors on Monday, January 27th. B. Riley analyst H. Goetsch now anticipates ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback